NEXS BioMedica Corporation
NEXS BioMedica is a pioneering biotechnology company dedicated to developing innovative precision medicine and targeted therapies for rare cancers, especially adrenocortical carcinoma. With a focus on science and technology, the company aims to transform healthcare delivery through breakthrough research, strategic partnerships, and advanced technology platforms. Their mission is to create life-changing therapies for the world's rarest and deadliest diseases, emphasizing health equity and patient safety.
Industries
Nr. of Employees
small (1-50)
NEXS BioMedica Corporation
Elkridge, Maryland, United States, North America
Products
mRNA delivery platform
Advanced mRNA delivery system engineered for enhanced stability, targeted cellular uptake, improved tissue penetration, and programmable release for therapeutic applications.
Nanoparticle targeted drug delivery platform
Nanoparticle carrier technology that leverages tumor-specific biomarkers for selective delivery of therapeutic compounds to cancer cells while minimizing off-target exposure.
AI-driven computational drug discovery platform
Computational platform that applies AI algorithms to analyze molecular interactions at scale, identify novel therapeutic candidates, and prioritize leads for preclinical testing.
Antibody-drug conjugate engineering platform
Platform for designing antibody-drug conjugates, including targeted antibody selection and linker chemistry to optimize delivery of cytotoxic payloads to tumor cells.
Cellular reprogramming platform
Toolkit of small-molecule combinations and methods aimed at reprogramming or eliminating cancer stem cells and therapy-resistant populations.
Bispecific antibody development platform
Development platform for creating bispecific proteins that engage tumor antigens and immune effectors simultaneously.
mRNA delivery platform
Advanced mRNA delivery system engineered for enhanced stability, targeted cellular uptake, improved tissue penetration, and programmable release for therapeutic applications.
Nanoparticle targeted drug delivery platform
Nanoparticle carrier technology that leverages tumor-specific biomarkers for selective delivery of therapeutic compounds to cancer cells while minimizing off-target exposure.
AI-driven computational drug discovery platform
Computational platform that applies AI algorithms to analyze molecular interactions at scale, identify novel therapeutic candidates, and prioritize leads for preclinical testing.
Antibody-drug conjugate engineering platform
Platform for designing antibody-drug conjugates, including targeted antibody selection and linker chemistry to optimize delivery of cytotoxic payloads to tumor cells.
Cellular reprogramming platform
Toolkit of small-molecule combinations and methods aimed at reprogramming or eliminating cancer stem cells and therapy-resistant populations.
Bispecific antibody development platform
Development platform for creating bispecific proteins that engage tumor antigens and immune effectors simultaneously.
Services
Global adverse event intake, signal detection, benefit-risk assessment, and regulatory safety reporting supported by a dedicated safety hotline and reporting workflows.
Design and operation of expanded access, compassionate use, and early access programs to provide investigational therapies to eligible patients and manage related governance.
Establishment and management of collaborative agreements with academic institutions, government agencies, and industry partners to accelerate research and development.
Global adverse event intake, signal detection, benefit-risk assessment, and regulatory safety reporting supported by a dedicated safety hotline and reporting workflows.
Design and operation of expanded access, compassionate use, and early access programs to provide investigational therapies to eligible patients and manage related governance.
Establishment and management of collaborative agreements with academic institutions, government agencies, and industry partners to accelerate research and development.
Expertise Areas
- Oncology drug discovery
- Rare disease therapeutics
- Targeted drug delivery
- Immuno-oncology (ADC and bispecific antibodies)
Key Technologies
- AI-driven drug discovery
- Cloud-based analytics
- mRNA delivery systems
- Nanoparticle drug delivery
News & Updates
Revolutionary AI-powered diagnostic tool enables early detection and personalized treatment planning for rare cancers, including adrenocortical carcinoma.
An investigation into the efficacy of NXS-4447 in targeting hypoxia-dependent pathways in adrenocortical carcinoma models.
NEXS BioMedica has over 20 years of experience in biotechnology research and development.
The company has published over 50 research articles in leading scientific journals.
NEXS BioMedica has filed more than 15 patents related to its innovative platforms and therapies.
The company collaborates with over 30 partners worldwide to advance its research and development.
Revolutionary AI-powered diagnostic tool enables early detection and personalized treatment planning for rare cancers, including adrenocortical carcinoma.
An investigation into the efficacy of NXS-4447 in targeting hypoxia-dependent pathways in adrenocortical carcinoma models.
NEXS BioMedica has over 20 years of experience in biotechnology research and development.
The company has published over 50 research articles in leading scientific journals.
NEXS BioMedica has filed more than 15 patents related to its innovative platforms and therapies.
The company collaborates with over 30 partners worldwide to advance its research and development.